180 related articles for article (PubMed ID: 19904799)
21. Synthesis and Biological Evaluation of Novel Epothilone B Side Chain Analogues.
Nicolaou KC; Rhoades D; Wang Y; Totokotsopoulos S; Bai R; Hamel E
ChemMedChem; 2015 Dec; 10(12):1974-9. PubMed ID: 26447977
[TBL] [Abstract][Full Text] [Related]
22. Synthesis of taxoids with improved cytotoxicity and solubility for use in tumor-specific delivery.
Miller ML; Roller EE; Zhao RY; Leece BA; Ab O; Baloglu E; Goldmacher VS; Chari RV
J Med Chem; 2004 Sep; 47(20):4802-5. PubMed ID: 15369381
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and Biological Evaluation of 7-Deoxy-Epothilone Analogues.
Woods LM; Arico JW; Frein JD; Sackett DL; Taylor RE
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28304361
[TBL] [Abstract][Full Text] [Related]
24. Structural basis of the activity of the microtubule-stabilizing agent epothilone a studied by NMR spectroscopy in solution.
Reese M; Sánchez-Pedregal VM; Kubicek K; Meiler J; Blommers MJ; Griesinger C; Carlomagno T
Angew Chem Int Ed Engl; 2007; 46(11):1864-8. PubMed ID: 17274084
[No Abstract] [Full Text] [Related]
25. Computational study of binding of epothilone A to β-tubulin.
Kamel K; Kolinski A
Acta Biochim Pol; 2011; 58(2):255-60. PubMed ID: 21633729
[TBL] [Abstract][Full Text] [Related]
26. The betaI/betaIII-tubulin isoforms and their complexes with antimitotic agents. Docking and molecular dynamics studies.
Magnani M; Ortuso F; Soro S; Alcaro S; Tramontano A; Botta M
FEBS J; 2006 Jul; 273(14):3301-10. PubMed ID: 16803461
[TBL] [Abstract][Full Text] [Related]
27. Tubulin: a target for antineoplastic drugs into the cancer cells but also in the peripheral nervous system.
Canta A; Chiorazzi A; Cavaletti G
Curr Med Chem; 2009; 16(11):1315-24. PubMed ID: 19355888
[TBL] [Abstract][Full Text] [Related]
28. Suppression of microtubule dynamics by epothilone B is associated with mitotic arrest.
Kamath K; Jordan MA
Cancer Res; 2003 Sep; 63(18):6026-31. PubMed ID: 14522931
[TBL] [Abstract][Full Text] [Related]
29. Tubulin interacting agents: novel taxanes and epothilones.
Agrawal NR; Ganapathi R; Mekhail T
Curr Oncol Rep; 2003 Mar; 5(2):89-98. PubMed ID: 12583825
[TBL] [Abstract][Full Text] [Related]
30. Comparative binding energy (COMBINE) analysis supports a proposal for the binding mode of epothilones to β-tubulin.
Coderch C; Klett J; Morreale A; Fernando Díaz J; Gago F
ChemMedChem; 2012 May; 7(5):836-43. PubMed ID: 22431398
[TBL] [Abstract][Full Text] [Related]
31. Peloruside A, a novel antimitotic agent with paclitaxel-like microtubule- stabilizing activity.
Hood KA; West LM; Rouwé B; Northcote PT; Berridge MV; Wakefield SJ; Miller JH
Cancer Res; 2002 Jun; 62(12):3356-60. PubMed ID: 12067973
[TBL] [Abstract][Full Text] [Related]
32. Differences in paclitaxel and docetaxel interactions with tubulin detected by mutagenesis of yeast tubulin.
Winefield RD; Entwistle RA; Foland TB; Lushington GH; Himes RH
ChemMedChem; 2008 Dec; 3(12):1844-7. PubMed ID: 18988212
[No Abstract] [Full Text] [Related]
33. The chemistry and biology of epothilones--the wheel keeps turning.
Altmann KH; Pfeiffer B; Arseniyadis S; Pratt BA; Nicolaou KC
ChemMedChem; 2007 Apr; 2(4):396-423. PubMed ID: 17340668
[No Abstract] [Full Text] [Related]
34. Diastereomers of dibromo-7-epi-10-deacetylcephalomannine: crowded and cytotoxic taxanes exhibit halogen bonds.
Jiang Y; Alcaraz AA; Chen JM; Kobayashi H; Lu YJ; Snyder JP
J Med Chem; 2006 Mar; 49(6):1891-9. PubMed ID: 16539375
[TBL] [Abstract][Full Text] [Related]
35. Microtubules: an overview.
Wade RH
Methods Mol Med; 2007; 137():1-16. PubMed ID: 18085218
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents.
Fojo T; Menefee M
Ann Oncol; 2007 Jul; 18 Suppl 5():v3-8. PubMed ID: 17656560
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis and biological evaluation of bridged epothilone D analogues.
Chen QH; Ganesh T; Brodie P; Slebodnick C; Jiang Y; Banerjee A; Bane S; Snyder JP; Kingston DG
Org Biomol Chem; 2008 Dec; 6(24):4542-52. PubMed ID: 19039362
[TBL] [Abstract][Full Text] [Related]
38. Epothilones: From discovery to clinical trials.
Forli S
Curr Top Med Chem; 2014; 14(20):2312-21. PubMed ID: 25434353
[TBL] [Abstract][Full Text] [Related]
39. SAR and pH stability of cyano-substituted epothilones.
Regueiro-Ren A; Leavitt K; Kim SH; Höfle G; Kiffe M; Gougoutas JZ; DiMarco JD; Lee FY; Fairchild CR; Long BH; Vite GD
Org Lett; 2002 Oct; 4(22):3815-8. PubMed ID: 12599466
[TBL] [Abstract][Full Text] [Related]
40. Conformation-activity relationships in polyketide natural products: a new perspective on the rational design of epothilone analogues.
Taylor RE; Chen Y; Beatty A; Myles DC; Zhou Y
J Am Chem Soc; 2003 Jan; 125(1):26-7. PubMed ID: 12515494
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
